Experimental cell therapy shows promise in rare sarcoma trial
NCT ID NCT05549921
First seen Jun 14, 2026 · Last updated Jun 18, 2026 · Updated 2 times
Summary
This study tested a new cell therapy called TAEST16001 in 8 adults with advanced soft tissue sarcoma who had specific genetic markers (HLA-A*02:01 and NY-ESO-1). The goal was to see if the treatment could shrink tumors. The trial was stopped early, so results are limited.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for SOFT TISSUE SARCOMA are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Locations
-
Peking University Cancer Hospital & Institute
Beijing, 100142, China
-
Sun Yat-Sen Univerisity Cancer Center
Guangzhou, Guangdong, China
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.